CluePoints Chief Scientific Officer and Pfizer’s Global RBM Program Lead to Speak at #CQOF2021
Will ICH E6 (R3) Unleash the Potential of Risk-Based Trials?
CluePoints Partners with ZS to Provide Best-in-Class RBQM Expertise and Technology, Increasing Clinical Trial Efficiency and Improving Patient Outcomes
CluePoints’ Launch Post-COVID Trial Assurance Solution
Software Engineering Skills for a Big Societal Impact
Introducing CluePoints’ Post-COVID Trial Assurance Solution
Using Risk-Based Monitoring to Focus on What Matters
Revealing the Bigger Picture Through Metadata & Building RBQM Standards of the Future
CluePoints Sponsors RBQM Live, The Definitive Guide to RBQM for Experts and Beginners
Find out where we’re headed next.
ICH E6 (R2)
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
ICH E6 (R2)
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.